In the study, 33 percent of patients receiving upadacitinib achieved clinical remission (per Adapted
(C) 2021 Electronic News Publishing, source
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
180.9 USD | +0.29% | +2.12% | +16.96% |
Mar. 27 | Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating | MT |
Mar. 25 | Deals of the day-Mergers and acquisitions | RE |
In the study, 33 percent of patients receiving upadacitinib achieved clinical remission (per Adapted
(C) 2021 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+16.96% | 319B | |
+35.79% | 701B | |
+26.24% | 571B | |
+1.10% | 381B | |
+20.45% | 334B | |
+0.89% | 210B | |
+2.32% | 210B | |
-6.36% | 201B | |
-3.25% | 157B | |
-0.85% | 153B |